MRKR Marker Therapeutics Inc.

+0.14  (+2%)
Previous Close 8.94
Open 9
Price To Book 7.44
Market Cap 412,999,106
Shares 45,484,483
Volume 183,813
Short Ratio
Av. Daily Volume 563,604

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 4Q 2019.
Platinum-sensitive ovarian cancer
26/27 patients have shown immune response.
Second line triple-negative breast cancer (TNBC)
Phase 1/2 data presented at ASH 2018.
MultiTAA-Specific T Cells
Multiple Myeloma
Phase 1/2 trial ongoing.
MultiTAA-Specific T Cells
Phase 2 trial to be initiated later in 2019.
MultiTAA-Specific T Cells
Acute Myeloid Leukemia
Phase 1/2 data to be presented July 20, 2019 at AACR.
MultiTAA-Specific T Cells
Pancreatic cancer

Latest News

  1. Hedge Funds Have Never Been This Bullish On Marker Therapeutics, Inc. (MRKR)
  2. Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma
  3. Will Marker Therapeutics Surge Higher?
  4. Marker Therapeutics to Present at Two Upcoming Investor Conferences
  5. Should Marker Therapeutics (NASDAQ:MRKR) Be Disappointed With Their 89% Profit?
  6. MARKER THERAPEUTICS, INC. (MRKR) Reports Q1 Loss, Lags Revenue Estimates
  7. Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results
  8. Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
  9. Here's Why Marker Therapeutics Fell as Much as 11.5% Today
  10. featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
  11. Marker Therapeutics Provides Business and Clinical Update
  12. These 5 Stocks Make Great Buys on New Analyst Coverage
  13. Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th
  14. Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
  15. Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award
  16. Marker Therapeutics to Present at the CAR-TCR Summit Europe
  17. Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility
  18. Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
  19. Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference
  20. Does Market Volatility Impact Marker Therapeutics, Inc.’s (NASDAQ:MRKR) Share Price?